-
The supplies will support the rollout of COVID-19 vaccines in low- and middle-income countries.
-
With misinformation casting a shadow over COVID-19 vaccine uptake, experts debate the issue.
-
All approved and candidate vaccines must now be tested against new COVID-19 variants.
-
The company says it could produce a billion doses of bulk RNA material per year within the next two years.
-
Preventing critical COVID-19 infection is important for both mother and foetus.
-
There was also an increase of 2.7 percentage points in those who were unsure and 3.3 percentage points in those who would definitely not.
-
Vaccination campaigns must not to seen as a race for the largest numbers at the quickest speed, ECDC director says.
-
This article is a correction of an article previously entitled:
-
A phase 1-2 trial found the vaccine elicited an immune response without any significant safety concerns.
-
Across 15 countries, people in the UK were the most willing to accept a vaccine offer.
-
There are concerns that immune responses to the vaccine may be diminished in some patients with IBD.
-
The data, published in the Lancet, suggest the vaccine has efficacy of more than 91 per cent.
-
The changing patterns of psychoactive drug injection in the UK is a cause for concern.
-
Clinical programmes address lower immunity against the South African variant.
Latest Updates